poisar

Stocks · News reference

Natera, TransCode Therapeutics Partnering To Support Enrollment For TransCode’s Phase 2a Study Of TTX-MC138 In Participants With Colorectal Cancer

Benzinga Newsdesk

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NTRARNAZ
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million

    Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption.

    RHHBYILMNNTRAQGENERRFY
  4. SEC EDGAR

    8-K filing — Transcode Therapeutics, Inc. (RNAZ)

    Filed: 2026-10-01 AccNo: 0001104659-26-112826 Size: 196 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

    RNAZ